- Home
- MDWD vs BETR Comparison
MDWD vs BETR Comparison
Compare MDWD & BETR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- BETR
- Stock Information
- Founded
- MDWD 2000
- BETR 2014
- Country
- MDWD Israel
- BETR United States
- Employees
- MDWD N/A
- BETR N/A
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- BETR Finance: Consumer Services
- Sector
- MDWD Health Care
- BETR Finance
- Exchange
- MDWD Nasdaq
- BETR Nasdaq
- Market Cap
- MDWD 230.6M
- BETR 218.6M
- IPO Year
- MDWD 2014
- BETR N/A
- Fundamental
- Price
- MDWD $19.09
- BETR $13.10
- Analyst Decision
- MDWD Strong Buy
- BETR
- Analyst Count
- MDWD 2
- BETR 0
- Target Price
- MDWD $35.00
- BETR N/A
- AVG Volume (30 Days)
- MDWD 59.0K
- BETR 80.9K
- Earning Date
- MDWD 08-13-2025
- BETR 08-07-2025
- Dividend Yield
- MDWD N/A
- BETR N/A
- EPS Growth
- MDWD N/A
- BETR N/A
- EPS
- MDWD N/A
- BETR N/A
- Revenue
- MDWD $19,213,000.00
- BETR $118,790,000.00
- Revenue This Year
- MDWD $20.80
- BETR N/A
- Revenue Next Year
- MDWD $26.92
- BETR N/A
- P/E Ratio
- MDWD N/A
- BETR N/A
- Revenue Growth
- MDWD N/A
- BETR 56.38
- 52 Week Low
- MDWD $12.78
- BETR $7.71
- 52 Week High
- MDWD $24.00
- BETR $30.00
- Technical
- Relative Strength Index (RSI)
- MDWD 37.96
- BETR 49.00
- Support Level
- MDWD $19.98
- BETR $13.43
- Resistance Level
- MDWD $20.95
- BETR $14.75
- Average True Range (ATR)
- MDWD 0.64
- BETR 1.01
- MACD
- MDWD -0.38
- BETR 0.12
- Stochastic Oscillator
- MDWD 0.29
- BETR 58.08
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
About BETR Better Home & Finance Holding Company
Better Home & Finance Holding Co is a digital-first homeownership company whose services include mortgage, real estate, title, and homeowners insurance. The company has combined technology innovation and fresh thinking with a deep customer focus with the goal of revolutionizing the homeownership industry.